AdipoRon
AdipoRon is an agonist at adiponectin receptors that increases secretion of AMPK and PPAR-α. AdipoRon exhibits anti-diabetic and cardioprotective activities and is in development as a potential treatment for type 2 diabetes mellitus (T2DM). In vivo, AdipoRon decreases insulin resistance and glucose tolerance, ameliorates diabetes, and increases lifespan. In animal models of myocardial ischemia/reperfusion, this compound improves cardiac function, decreases oxidative stress, and inhibits post-ischemic cardiomyocyte apoptosis.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18836071
| Cas No. |
924416-43-3 |
|---|---|
| Purity |
≥98% |
| Formula |
C27H28N2O3 |
| Formula Wt. |
428.53 |
| Chemical Name |
2-(4-Benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamide |
| IUPAC Name |
2-(4-Benzoylphenoxy)-N-(1-benzyl-4-piperidinyl)acetamide |
| Solubility |
Soluble in DMSO, 100% ethanol or methanol. Insoluble in water |
| Appearance |
White solid |
Zhang Y, Zhao J, Li R, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015 Aug 1;309(3):E275-82.PMID: 26037251.
Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013 Nov 28;503(7477):493-9. PMID: 24172895.
